SAN DIEGO — The absolute change in FVC at 48 weeks was similar between patients with idiopathic pulmonary fibrosis receiving pamrevlumab vs. placebo, according to a presentation at the American Thoracic Society International Conference.Pamrevlumab (FibroGen) is a fully human monoclonal antibody that impedes connective tissue growth factor, according to researchers.
Pamrevlumab Treatment for Idiopathic Pulmonary Fibrosis miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.